Vitamin A and D supplements after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether taking vitamin A and D after a stem cell transplant can help improve recovery. It is for people with certain blood cancers who have a matched donor and are in remission or have low disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer like acute leukemia, myelodysplastic syndrome, or multiple myeloma.
- Your disease is in remission or mostly controlled (few cancer cells in bone marrow or blood).
- You have a related or unrelated donor with a good HLA match (10/10 or 9-10/10).
- You are 18 years or older and generally healthy without major organ problems.
- You have not had a prior stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding dexamethasone, intravenous immunoglobulin, and extra donor cells can lower donor-specific antibodies in people receiving half-matched stem cell transplants. The goal is to help more patients safely get a transplant when fully matched donors aren't available.
This trial tests a stronger chemotherapy and radiation regimen before a donor stem cell transplant for people with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to eliminate any remaining cancer cells and improve transplant success.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial is for people with high-risk acute lymphoblastic leukemia who are getting a stem cell transplant from a family donor. After transplant, you'd receive a treatment that combines specially designed immune cells (CAR T cells) that target your leukemia, plus a vaccine that helps those cells work better.
This trial tests whether the drug interferon alfa can help prevent blood cancer from coming back after a stem cell transplant. It is for people with certain types of blood cancer (MDS or AML with a TP53 mutation) who had no detectable cancer cells when checked after transplant.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.